Advertisement
Screener

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Increase (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31)

2.8 / 5 stars · 68/120 Roast Me

IOVANCE BIOTHERAPEUTICS, INC. Increase (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31)

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Increase (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) of $0 for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-10-23.

Discontinued › Notes

us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments · last filed 2013-10-23

  • IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in fair value of derivative instruments, not designated as hedging instruments (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $0.00.
  • IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in fair value of derivative instruments, not designated as hedging instruments (deprecated 2013-01-31) for the quarter ending 2012-12-31 was $7.66M.
  • IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in fair value of derivative instruments, not designated as hedging instruments (deprecated 2013-01-31) for the quarter ending 2012-09-30 was $1.60M, a 54.99% decline year-over-year.
  • IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in fair value of derivative instruments, not designated as hedging instruments (deprecated 2013-01-31) for the quarter ending 2012-06-30 was $1.93M.
  • IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in fair value of derivative instruments, not designated as hedging instruments (deprecated 2013-01-31) for fiscal 2012 was $8.64M, a 441.04% increase from fiscal 2011.
  • IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in fair value of derivative instruments, not designated as hedging instruments (deprecated 2013-01-31) for fiscal 2011 was $1.60M.
  • IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in fair value of derivative instruments, not designated as hedging instruments (deprecated 2013-01-31) for fiscal 2010 was -$229.23K.
  • IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in fair value of derivative instruments, not designated as hedging instruments (deprecated 2013-01-31) for fiscal 2009 was $0.00.
Period endIncrease (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) 3 monthIncrease (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) 6 monthIncrease (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) 9 monthIncrease (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) 12 monthIncrease (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) 45 monthIncrease (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) 48 monthIncrease (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) 51 monthIncrease (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) 54 monthIncrease (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) 57 monthIncrease (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) 60 monthIncrease (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) 63 monthIncrease (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) 66 month
2013-03-31$0.00
10-Q · filed 2013-10-23
$7.66M
derived: sum of 2 quarters · filed 2013-10-23
$9.26M
derived: sum of 3 quarters · filed 2013-10-23
$11.18M
derived: sum of 4 quarters · filed 2013-10-23
$10.00M
10-Q · filed 2013-10-23
2012-12-31$7.66M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-23
$9.26M
derived: sum of 2 quarters · filed 2013-09-23
$11.18M
derived: sum of 3 quarters · filed 2013-09-23
$8.64M
10-K · filed 2013-09-23
$10.00M
10-K · filed 2013-09-23
2012-09-30$1.60M
10-Q · filed 2013-01-25
$3.52M
derived: sum of 2 quarters · filed 2013-01-25
$975.70K
10-Q · filed 2013-01-25
-$669.71K
derived: sum of 4 quarters · filed 2013-10-23
$2.34M
10-Q · filed 2013-01-25
2012-06-30$1.93M
10-Q/A · filed 2012-09-10
-$620.24K
10-Q/A · filed 2012-09-10
-$2.27M
derived: sum of 3 quarters · filed 2013-10-23
$1.28M
derived: sum of 4 quarters · filed 2013-10-23
$746.57K
10-Q/A · filed 2012-09-10
2012-03-31-$2.55M
10-Q · filed 2013-10-23
-$4.19M
derived: sum of 2 quarters · filed 2013-10-23
-$647.44K
derived: sum of 3 quarters · filed 2013-10-23
-$1.05M
derived: sum of 4 quarters · filed 2013-10-23
-$1.18M
10-Q · filed 2012-05-15
2011-12-31-$1.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-23
$1.90M
derived: sum of 2 quarters · filed 2013-09-23
$1.50M
derived: sum of 3 quarters · filed 2013-09-23
$1.60M
10-K · filed 2013-09-23
$1.37M
10-K · filed 2012-03-30
2011-09-30$3.55M
10-Q · filed 2013-01-25
$3.15M
derived: sum of 2 quarters · filed 2013-01-25
$3.24M
10-Q · filed 2013-01-25
$3.00M
derived: sum of 4 quarters · filed 2013-01-25
$3.01M
10-Q · filed 2011-11-21
2011-06-30-$398.56K
10-Q/A · filed 2012-09-10
-$304.60K
10-Q/A · filed 2012-09-10
-$550.45K
derived: sum of 3 quarters · filed 2012-09-10
-$533.83K
derived: sum of 4 quarters · filed 2012-09-10
-$533.83K
10-Q/A · filed 2011-09-01
2011-03-31$93.95K
10-Q · filed 2012-05-15
-$151.89K
derived: sum of 2 quarters · filed 2012-05-15
-$135.27K
derived: sum of 3 quarters · filed 2012-05-15
-$135.27K
derived: sum of 4 quarters · filed 2012-05-15
2010-12-31-$245.84K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-30
-$229.23K
derived: sum of 2 quarters · filed 2012-03-30
-$229.23K
derived: sum of 3 quarters · filed 2012-03-30
-$229.23K
10-K · filed 2012-03-30
2010-09-30$16.62K
10-Q · filed 2011-11-21
$16.62K
derived: sum of 2 quarters · filed 2011-11-21
$16.62K
10-Q · filed 2011-11-21
2010-06-30$0.00
10-Q/A · filed 2011-09-01
$0.00
10-Q/A · filed 2011-09-01
2009-12-31$0.00
10-K · filed 2012-03-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Greenland Mines Ltd (GRML)United States$2.362B